Everolimus Shows No Neurocognitive Benefit in Trial
A study of adults with tuberous sclerosis complex found the drug had no significant effect on memory or executive function.
Updated on Oct. 23, 2026 in Alzheimer’s
A clinical trial evaluating the mTOR inhibitor everolimus in patients with tuberous sclerosis complex found no significant difference in neuropsychological outcomes compared to a placebo. The study involved 38 participants aged 16 to 60 who were monitored over a 24-week period.
Why it matters
Researchers are investigating whether targeting specific cellular pathways can improve cognitive function in those with tuberous sclerosis complex. Understanding these outcomes is critical for designing future therapies to address the complex neuropsychological needs of this population.
This multicentre randomised controlled trial followed 38 participants aged 16-60 over 24 weeks to assess neuropsychological functioning. Researchers observed a response rate of 87% in the everolimus group compared to 75% in the placebo group, though the clinical significance of these findings remains unknown.
The details
The TRON trial utilized everolimus, an mTOR inhibitor, to determine if the drug could influence executive function and memory in patients with tuberous sclerosis complex. Participants received the treatment or a placebo over a 24-week course, with researchers conducting retests at baseline and four subsequent intervals. Adverse events were noted in 22 of 25 participants in the treatment arm compared to 8 of 13 in the placebo arm.
Timeline
Participants received everolimus or a placebo for a period of 24 weeks.
Health Landscape
The TRON trial provides a foundational assessment for future neuropsychological research in tuberous sclerosis complex, moving beyond existing symptom-focused care. This study updates the current evidence base by providing direct data on the effect of mTOR inhibitors on neurocognitive domains.
These findings are limited to a clinical trial setting and do not indicate a change in current standard treatments for tuberous sclerosis complex. Patients and families should discuss any questions regarding cognitive health or medication options with their primary neurologist.
The takeaway
While the trial explored the potential of mTOR inhibitors for cognitive support, current results do not support a clinical shift in care. Consult with a neurologist regarding evidence-based strategies for managing neuropsychological symptoms associated with tuberous sclerosis complex.
Further reading
For more on neurocognitive research and related treatments, visit our Alzheimer’s section.
Source note: This article includes information reported by Journal of Medical Genetics.
